Lydia Kalafati

Lydia Kalafati

Auto-generated profile, based on publicly available information

Lydia Kalafati

Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, TU Dresden, Dresden 01307, Germany; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden 01328, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell
Verified
Journal Article
Open access
LKLydia Kalafati
Lydia Kalafati
IKIoannis Kourtzelis
Ioannis Kourtzelis
JSJonas Schulte-Schrepping
Jonas Schulte-Schrepping
XLXiaofei Li
Xiaofei Li
AHAikaterini Hatzioannou
Aikaterini Hatzioannou
TCTriantafyllos Chavakis
Triantafyllos Chavakis
Trained innate immunity, induced via modulation of mature myeloid cells or their bone marrow progenitors, mediates sustained increased responsiveness to secondary challenges. Here, we investigated whether anti-tumor immunity can be enhanced through induction of trained immunity. Pre-treatment of mice with β-glucan, a fungal-derived prototypical agonist of trained immunity, resulted in diminished tumor growth. The anti-tumor effect of β-glucan-induced trained immunity was associated with transcriptomic and epigenetic rewiring of granulopoiesis and neutrophil reprogramming toward an anti-tumor phenotype; this process required type I interferon signaling irrespective of adaptive immunity in the host. Adoptive transfer of neutrophils from β-glucan-trained mice to naive recipients suppressed tumor growth in the latter in a ROS-dependent manner. Moreover, the anti-tumor effect of β-glucan-induced trained granulopoiesis was transmissible by bone marrow transplantation to recipient naive mice. Our findings identify a novel and therapeutically relevant anti-tumor facet of trained immunity involving appropriate rewiring of granulopoiesis.

1 November 2020 in Cell Reports
Verified
Journal Article
Open access
SMSimone J.C.F.M. Moorlag
Simone J.C.F.M. Moorlag
YRYessica Alina Rodriguez-Rosales
Yessica Alina Rodriguez-Rosales
JGJoshua Gillard
Joshua Gillard
SFStephanie Fanucchi
Stephanie Fanucchi
KTKate Theunissen
Kate Theunissen
MNMihai G. Netea
Mihai G. Netea
The tuberculosis vaccine bacillus Calmette-Guérin (BCG) protects against some heterologous infections, probably via induction of non-specific innate immune memory in monocytes and natural killer (NK) cells, a process known as trained immunity. Recent studies have revealed that the induction of trained immunity is associated with a bias toward granulopoiesis in bone marrow hematopoietic progenitor cells, but it is unknown whether BCG vaccination also leads to functional reprogramming of mature neutrophils. Here, we show that BCG vaccination of healthy humans induces long-lasting changes in neutrophil phenotype, characterized by increased expression of activation markers and antimicrobial function. The enhanced function of human neutrophils persists for at least 3 months after vaccination and is associated with genome-wide epigenetic modifications in trimethylation at histone 3 lysine 4. Functional reprogramming of neutrophils by the induction of trained immunity might offer novel therapeutic strategies in clinical conditions that could benefit from modulation of neutrophil effector function.

27 April 2022 in Cell
Verified
Journal Article
Closed access
XLXiaofei Li
Xiaofei Li
HWHui Wang
Hui Wang
XYXiang Yu
Xiang Yu
GSGundappa Saha
Gundappa Saha
LKLydia Kalafati
Lydia Kalafati
GHGeorge Hajishengallis
George Hajishengallis

1 December 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
XLXiaofei Li
Xiaofei Li
ACAlessandra Colamatteo
Alessandra Colamatteo
LKLydia Kalafati
Lydia Kalafati
TKTetsuhiro Kajikawa
Tetsuhiro Kajikawa
HWHui Wang
Hui Wang
GHGeorge Hajishengallis
George Hajishengallis
FOXP3+CD4+ regulatory T cells (Tregs) are critical for immune homeostasis and respond to local tissue cues, which control their stability and function. We explored here whether developmental endothelial locus-1 (DEL-1), which, like Tregs, increases during resolution of inflammation, promotes Treg responses. DEL-1 enhanced Treg numbers and function at barrier sites (oral and lung mucosa). The underlying mechanism was dissected using mice lacking DEL-1 or expressing a point mutant thereof, or mice with T cell–specific deletion of the transcription factor RUNX1, identified by RNA sequencing analysis of the DEL-1–induced Treg transcriptome. Specifically, through interaction with αvβ3 integrin, DEL-1 promoted induction of RUNX1-dependent FOXP3 expression and conferred stability of FOXP3 expression upon Treg restimulation in the absence of exogenous TGF-β1. Consistently, DEL-1 enhanced the demethylation of the Treg-specific demethylated region (TSDR) in the mouse Foxp3 gene and the suppressive function of sorted induced Tregs. Similarly, DEL-1 increased RUNX1 and FOXP3 expression in human conventional T cells, promoting their conversion into induced Tregs with increased TSDR demethylation, enhanced stability, and suppressive activity. We thus uncovered a DEL-1/αvβ3/RUNX1 axis that promotes Treg responses at barrier sites and offers therapeutic options for modulating inflammatory/autoimmune disorders.

6 January 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
ELEleftheria Lamprianidou
Eleftheria Lamprianidou
CKChryssoula Kordella
Chryssoula Kordella
AKAnastasiya Kazachenka
Anastasiya Kazachenka
EZEmmanouela Zoulia
Emmanouela Zoulia
EBElsa Bernard
Elsa Bernard
IKIOANNIS KOTSIANIDIS
IOANNIS KOTSIANIDIS
CD4+ T cells orchestrate immune responses and are actively engaged in shaping tumor immunity. Signal transducer and activator of transcription (STAT) signaling controls the epigenetic tuning of CD4+ T-cell differentiation and polarization, and perturbed STAT signaling networks in CD4+ T cells subvert antitumor immunity in malignancies. Azacitidine (AZA), the mainstay therapy for high-risk myelodysplastic syndromes (HR-MDS), affects CD4+ T-cell polarization and function, but whether this contributes to AZA efficacy is currently unknown. By using functional proteomic, transcriptomic, and mutational analyses in 73 HR-MDS patients undergoing AZA therapy, we demonstrate that responding patients exhibited a coordinated CD4+ T-cell immune response and downregulated the inflammatory cytokine signaling pathways in CD4+ T cells after AZA, in contrast to nonresponders who upregulated the same pathways. We further observed an AZA-mediated downregulation of intereukin-6 (IL-6)—induced STAT3 phosphorylation in CD4+FOXP3− conventional T cells (Tcons) that correlated independently with better response and survival, whereas it was also not associated with the mutation number and profile of the patients. The AZA-induced downregulation of IL-6/STAT3 axis in Tcons restored the STAT signaling architecture in CD4+ T-cell subsets, whereas STAT signaling networks remained disorganized in patients who upregulated IL-6/STAT3 activity in Tcons. Given the pivotal role of CD4+ T cells in adaptive immunity, our findings suggest that the downregulation of the IL-6/STAT3 pathway in Tcons potentially constitutes a previously unrecognized immune-mediated mechanism of action of AZA and sets the scene for developing rational strategies of AZA combinations with IL-6/STAT3 axis inhibitors.

15 June 2026 in Seminars in Immunology
Verified
Journal Article
Open access
DXDespoina Xanthopoulou
Despoina Xanthopoulou
MCMaria Crespo
Maria Crespo
LKLydia Kalafati
Lydia Kalafati
Interleukin-1 (IL-1) exerts a pivotal role in the regulation of innate immune responses and inflammatory processes. Beyond its local effects at the site of inflammation, IL-1 acts as a systemic regulator of hematopoiesis by reprogramming hematopoietic stem and progenitor cells (HSPCs), thereby shaping the functional properties of the myeloid progeny. Through induction of emergency myelopoiesis and inflammatory memory, IL-1 can imprint durable epigenetic, metabolic and transcriptomic changes within the hematopoietic compartment, altering immune output well beyond the initial inflammatory trigger. This systemic effect of IL-1 signaling is particularly relevant in the context of cancer, since tumors are now viewed as inflammatory entities providing persistent inflammatory factors that can influence hematopoiesis and imprint an immunosuppressive phenotype in myeloid cells. In parallel, aging and clonal hematopoiesis (CH) are characterized by chronic low-grade inflammation in which IL-1 signaling may amplify mutant progenitor expansion, linking inflammaging to increased susceptibility to both hematological malignancies and solid cancers. Here, we discuss the role of IL-1 signaling in emergency myelopoiesis and both central and peripheral inflammatory memory, and how these processes shape cancer progression. We also highlight the therapeutic potential of targeting IL-1-mediated hematopoietic reprogramming.